Literature DB >> 31415880

Controlled release of doxorubicin from polyethylene glycol functionalized melanin nanoparticles for breast cancer therapy: Part I. Production and drug release performance of the melanin nanoparticles.

Busra Ozlu1, Gozde Kabay2, Ilyas Bocek3, Merve Yilmaz4, Ayse Kevser Piskin4, Bong Sup Shim5, Mehmet Mutlu6.   

Abstract

In this study, polyethylene glycol (PEG) conjugated melanin nanoparticles (MNPs) were prepared (PEG-MNPs). A model chemotherapy drug, doxorubicin (DOX), was loaded into the PEG-MNPs with varied concentrations (0.125, 0.250, 0.500 mg/mL). TEM images showed that, DOX-PEG-MNPs are spherical-shaped and 15 ± 2.2 nm in diameter. FTIR spectroscopy analysis demonstrated that MNPs were successfully modified with PEG. The UV-Vis spectroscopy results showed that the drug loading capacity of MNPs was 0.7 mg/ml of DOX in 2 mg/ml of PEG-MNPs. The time course data showed that, the release behavior of DOX from MNPs was primarily diffusion controlled. In vitro cytotoxicity assays demonstrated that MNP and PEG-MNP did not show any toxic effect on mouse fibroblast cells while DOX-PEG-MNP was able to inhibit the proliferation of human breast cancer cells. The results confirm that the application area of MNPs in controlled and prolonged drug release could be extended to the different types of cancer therapeutics.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Controlled release; Doxorubicin; Melanin nanoparticle; Nano-sized drug delivery

Mesh:

Substances:

Year:  2019        PMID: 31415880     DOI: 10.1016/j.ijpharm.2019.118613

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Production, purification, and characterization of Streptomyces sp. strain MPPS2 extracellular pyomelanin pigment.

Authors:  Sinan Bayram
Journal:  Arch Microbiol       Date:  2021-06-14       Impact factor: 2.552

Review 2.  Roles of Thyroid Hormone-Associated microRNAs Affecting Oxidative Stress in Human Hepatocellular Carcinoma.

Authors:  Po-Shuan Huang; Chia-Siu Wang; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

Review 3.  Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy.

Authors:  Cristina Adriana Dehelean; Iasmina Marcovici; Codruta Soica; Marius Mioc; Dorina Coricovac; Stela Iurciuc; Octavian Marius Cretu; Iulia Pinzaru
Journal:  Molecules       Date:  2021-02-19       Impact factor: 4.411

Review 4.  Melanin and Melanin-Functionalized Nanoparticles as Promising Tools in Cancer Research-A Review.

Authors:  Iasmina Marcovici; Dorina Coricovac; Iulia Pinzaru; Ioana Gabriela Macasoi; Roxana Popescu; Raul Chioibas; Istvan Zupko; Cristina Adriana Dehelean
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

5.  Melanin nanoparticles enhance the neuroprotection of mesenchymal stem cells against hypoxic-ischemic injury by inhibiting apoptosis and upregulating antioxidant defense.

Authors:  Chunliu Tang; Jiefeng Luo; Xianjia Yan; Qiaojuan Huang; Zhenhua Huang; Qi Luo; Yuan Lan; Dingzhi Chen; Baolin Zhang; Menghua Chen; Deyan Kong
Journal:  Cell Biol Int       Date:  2022-02-22       Impact factor: 4.473

Review 6.  Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.

Authors:  Mina Zare; Rakesh Pemmada; Maya Madhavan; Aswathy Shailaja; Seeram Ramakrishna; Sumodan Padikkala Kandiyil; James M Donahue; Vinoy Thomas
Journal:  Pharmaceutics       Date:  2022-08-03       Impact factor: 6.525

7.  Synthesis and Characterization of a Novel Dual-Responsive Nanogel for Anticancer Drug Delivery.

Authors:  Darya Aminoleslami; Sahar Porrang; Parviz Vahedi; Soodabeh Davaran
Journal:  Oxid Med Cell Longev       Date:  2022-09-19       Impact factor: 7.310

Review 8.  Chitosan Derivatives and Their Application in Biomedicine.

Authors:  Wenqian Wang; Qiuyu Meng; Qi Li; Jinbao Liu; Mo Zhou; Zheng Jin; Kai Zhao
Journal:  Int J Mol Sci       Date:  2020-01-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.